Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs
Executive Summary
The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.
You may also be interested in...
NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic
The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.
‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.